好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association of Structural Imaging of Hippocampal and Regional Brain Volumes with Retinal Optical Coherence Tomography Imaging in the Aging-MCI-AD Continuum: An ONDRI Study
Aging, Dementia, and Behavioral Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
9-006

To quantify the contribution of macula total retinal thickness and peripapillary retinal nerve fiber layer (pRNFL) thickness towards estimating hippocampal and regional brain volumes.

With atrophy and Alzheimer disease pathology detected in the retina as well as the brain, measuring retinal thickness using optical coherence tomography imaging may help estimate the volume of diagnostically and prognostically important brain regions to aid early disease detection.

Participants with either healthy aging, mild cognitive impairment or Alzheimer disease from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) cohort were included. Measures included hippocampal and normal appearing grey and white matter volumes of four brain lobes and remaining basal ganglia / thalamus region, and macula total retinal thickness and pRNFL thickness. Canonical correlation analysis (CCA) measured the correlation of brain and retinal measures. Brain measures were estimated using retinal measures adjusted for head size, age, sex, diagnosis and years of education using partial least squares (PLS) and ordinary least squares (OLS), with effect sizes reported as standardized regression coefficients and 2.

134 participants were included. Non-fovea macula explained about 7% of variability of a latent variable of brain measures based on CCA commonality analysis. Retinal measures only weakly estimated brain measures (2 typically<0.05 or negative) using PLS or OLS, including for diagnostically and prognostically important brain regions like the hippocampus and temporal lobe. Standardized OLS coefficients for hippocampal volume were small and about -0.05 to +0.05. Effect sizes were larger in women, for example when using OLS to estimate total brain volume from inferior pRNFL (2=0.08, std. beta=0.14, p<0.01) or temporal lobe grey matter from total pRNFL (2=0.03, std. beta=0.15, p<0.05).

Macula total retinal thickness or pRNFL thickness on their own appear to have a limited ability to estimate hippocampal or large regional brain volumes at baseline.

Authors/Disclosures
M. Amin Banihashemi
PRESENTER
Mr. Banihashemi has nothing to disclose.
Richard H. Swartz, BSc MD PhD FRCPC (Sunnybrook Health Sciences Centre) The institution of Dr. Swartz has received research support from Heart and Stroke Foundation of Canada. The institution of Dr. Swartz has received research support from Ontario Brain Institute.
Peter Kertes (University of Toronto) Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Peter Kertes has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Peter Kertes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apellis. Peter Kertes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astellas. Peter Kertes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novelty Nobility. Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson and Johnson. Peter Kertes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kriya. Peter Kertes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Admare Bio-innovations. Peter Kertes has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer. Peter Kertes has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Amgen. The institution of Peter Kertes has received research support from Roche. The institution of Peter Kertes has received research support from Novartis. The institution of Peter Kertes has received research support from Bayer. The institution of Peter Kertes has received research support from RegenxBio. The institution of Peter Kertes has received research support from Johnson and Johnson. The institution of Peter Kertes has received research support from Neuracle Genetics.
Wendy Hatch (University of Toronto) No disclosure on file
Christopher Hudson (University of Waterloo) No disclosure on file
Maged Goubran, PhD (Stanford University) Dr. Goubran has nothing to disclose.
Sandra E. Black, MD, FAAN (Sunnybrook Health Science Center) Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.